

**South East London
Integrated Medicines Optimisation Committee (SEL IMOC)**

**Withdrawal of position statement 003
(issued June 2017)**

Biosimilar insulin glargine marketed in the UK as Abasaglar®

Following advice from the Diabetes sub-group of the South East London Integrated Medicines Optimisation Committee (SEL IMOC), this position statement has been retired and withdrawn.

Information on insulin glargine preparations approved in South East London can be found in the [South East London Adult Joint Medicines Formulary](#) and the [South East London Paediatric Formulary](#) (registration required).

February 2026